Advertisement

Topics

Takeda Submits Vedolizumab NDA for Treatment of Moderately to Severe UC in Japan

13:48 EDT 23 Aug 2017 | Drug Discovery Development

Results from Study CCT-101 will be presented at scientific meeting in the future.
Contributed Author: 
Takeda Pharmaceuticals
Topics: 

Original Article: Takeda Submits Vedolizumab NDA for Treatment of Moderately to Severe UC in Japan

NEXT ARTICLE

More From BioPortfolio on "Takeda Submits Vedolizumab NDA for Treatment of Moderately to Severe UC in Japan"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...